Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Torti

Showing results (181-190 of 263) with videos related to

Pageof 27
Sort By:
The Journal of Infectious Diseases|December 11, 2012
Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes, Dominique Costagliola, Bruno Ledergerber, et al.
Medicine|July 22, 2016
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort studyEmanuele Focà, Massimiliano Fabbiani, Mattia Prosperi, et al.
The American Journal of Tropical Medicine and Hygiene|September 25, 2020
Evidence of Low Prevalence of Cystic Echinococcosis in the Catanzaro Province, Calabria Region, ItalyTommaso Manciulli, Riccardo Serraino, Gian Luca D'Alessandro, et al.
BMC Infectious Diseases|February 16, 2012
Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenzEmanuele Focà, Davide Motta, Marco Borderi, et al.
AIDS Patient Care and Stds|January 11, 2011
Clinical evaluation of the potential utility of computational modeling as an HIV treatment selection tool by physicians with considerable HIV experienceBrendan A Larder, Andrew Revell, Joann M Mican, et al.
BMC Infectious Diseases|July 16, 2005
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER CohortCarlo Torti, Giuseppe Lapadula, Salvatore Casari, et al.
Epidemiologia E Prevenzione|July 12, 2019
[Good practices for the surveillance and control of antimicrobial resistance]Maria Luisa Moro, Marta Ciofi Degli Atti, Carmen D'Amore, et al.
International Journal of Antimicrobial Agents|October 3, 2006
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patientsCarlo Torti, Giuseppe Lapadula, Maria Cristina Uccelli, et al.
Plos One|September 16, 2016
Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral TreatmentGiuseppe Lapadula, Davide Paolo Bernasconi, Salvatore Casari, et al.
Medicine|November 3, 2021
Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experienceMaria Mazzitelli, Arturo Ciccullo, Gianmaria Baldin, et al.
Pageof 27

Showing results (181-190 of 263) with videos related to

Sort By:
Pageof 27
The Journal of Infectious Diseases|December 11, 2012
Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes, Dominique Costagliola, Bruno Ledergerber, et al.
Medicine|July 22, 2016
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort studyEmanuele Focà, Massimiliano Fabbiani, Mattia Prosperi, et al.
The American Journal of Tropical Medicine and Hygiene|September 25, 2020
Evidence of Low Prevalence of Cystic Echinococcosis in the Catanzaro Province, Calabria Region, ItalyTommaso Manciulli, Riccardo Serraino, Gian Luca D'Alessandro, et al.
BMC Infectious Diseases|February 16, 2012
Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenzEmanuele Focà, Davide Motta, Marco Borderi, et al.
AIDS Patient Care and Stds|January 11, 2011
Clinical evaluation of the potential utility of computational modeling as an HIV treatment selection tool by physicians with considerable HIV experienceBrendan A Larder, Andrew Revell, Joann M Mican, et al.
BMC Infectious Diseases|July 16, 2005
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER CohortCarlo Torti, Giuseppe Lapadula, Salvatore Casari, et al.
Epidemiologia E Prevenzione|July 12, 2019
[Good practices for the surveillance and control of antimicrobial resistance]Maria Luisa Moro, Marta Ciofi Degli Atti, Carmen D'Amore, et al.
International Journal of Antimicrobial Agents|October 3, 2006
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patientsCarlo Torti, Giuseppe Lapadula, Maria Cristina Uccelli, et al.
Plos One|September 16, 2016
Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral TreatmentGiuseppe Lapadula, Davide Paolo Bernasconi, Salvatore Casari, et al.
Medicine|November 3, 2021
Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experienceMaria Mazzitelli, Arturo Ciccullo, Gianmaria Baldin, et al.
Pageof 27